Alpha-Gal-based Vaccine for Chagas Disease

The glycoconjugate (neoglycopeptide)-based vaccine candidate is structurally simple, chemically-stable, and efficiently produced in a large-scale. The effect of the alpha-Gal-containing glycotope position within the vaccine molecule on the immune responses is explored for the first time. The synthetic Galα3LN and closely-related neoglycopeptides are used as candidates for this preventative and therapeutic vaccine. Chao Zhang 915-747-6717

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More